Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality.
about
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsAssociations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study.Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural NigeriaSynthesis of Oxadiazolyl, Pyrazolyl and Thiazolyl Derivatives of Thiophene-2-Carboxamide as Antimicrobial and Anti-HCV Agents.Role of intrafamilial transmission in high prevalence of hepatitis C virus in Egypt.Evidence of intense ongoing endemic transmission of hepatitis C virus in EgyptSerum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia.Hepatitis C virus and other risk factors in hepatocellular carcinoma.Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt.Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health.Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors.The prevalence of functional dyspepsia using Rome III questionnaire among chronic hepatitis C patients.Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients.Epidemiology of hepatitis C virus exposure in Egypt: Opportunities for prevention and evaluation.Global control of hepatitis C: where challenge meets opportunitySerum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C.Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patientsCancer burden in Africa and opportunities for prevention.Toll-like receptor 3 gene expression in Egyptian patients with glomerulonephritis and hepatitis C virus infection.Potential market size and impact of hepatitis C treatment in low- and middle-income countries.Towards realistic estimates of HCV incidence in Egypt.Is irritable bowel syndrome associated with chronic hepatitis C?Assessment of antisperm antibodies in a sample of Egyptian patients with hepatitis C virus infection.Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway.Functional and morphological myocardial changes in hepatitis C virus patients with end-stage liver disease.Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.Quantifying current hepatitis C virus incidence in Egypt.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates
P2860
Q30365599-BD4665BF-F2D3-4D58-AE03-87E92E52E2B6Q30392599-7474ACDC-570A-4BB7-8C63-6AC8DF199BEFQ33349504-A092F6DC-12C4-4C3F-A421-0C2F7CD8C968Q33668443-BF683F8E-FCF0-4F74-A8FC-D79E841A19E4Q33812849-A497EFA6-A07E-454C-9247-EC31231A2C88Q34093173-EB38EF1E-5D8C-4B61-BB95-848C7C3E1A70Q34256849-E2C750A5-03F1-468E-9114-16C3E12B3432Q34763225-2B994FD1-3416-4C30-8C9F-E82DC6C23F1CQ35058571-8291EF26-A5ED-4EAC-A178-C10C071183A1Q35194411-8638506B-D116-4F38-B6DF-A86F6B38574CQ35690458-412E382B-7C63-4AF4-A5BB-9F4304580E5BQ35837823-FCC6CB14-B64A-43E3-B079-B75455019093Q35945404-50CA257B-8BFB-4F9C-9B58-1EB2A3732F44Q36072412-C1085FC0-03B6-4934-BC45-13252685E3F0Q36350001-EA6623C4-E898-404B-8166-FA947DFEF180Q37077112-2752704B-DE38-455C-832C-A26B92414F01Q37157863-05B336E6-2821-4D40-BC6C-4D95CCE177E0Q37634828-746BB0D7-2A7F-4F7C-A76B-F1040648A2E1Q37976577-6C2E398C-1928-4799-B165-89201C51D128Q38857778-7D835139-9099-41CD-9454-8E04818F910EQ38902281-730D2D57-0AB2-4A9F-B33A-BF3DEBEC1EF7Q38920434-ECD650CC-025C-4389-BCB6-781969A73520Q39009387-B95BD616-EC1A-45B6-9900-166103116C0DQ39089789-E2E81AD1-E139-499B-B549-C9EA28E32701Q39894712-412583CA-887B-4530-8FCD-960BCC3081B1Q42159699-35184548-CCD7-4B52-91E7-3ADAA8B0ACE4Q42988617-1A570AA0-80D7-4619-89AE-D5A3394CE8BCQ44394482-1517D802-F19F-4BD7-B71F-52239D4C86F1Q45350166-B249A4C3-D7DF-4C66-8DEA-B3CE0D2F65F5Q45356128-7BC170CA-ED60-4DA1-8151-7D0472C7B91DQ56532291-20E02DAE-058B-4FC5-AC30-706421D1BC61
P2860
Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@en
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@nl
type
label
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@en
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@nl
prefLabel
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@en
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@nl
P1476
Epidemic hepatitis C virus inf ...... uture morbidity and mortality.
@en
P2093
E M Lehman
M L Wilson
P304
P356
10.1111/J.1365-2893.2009.01115.X
P577
2009-04-20T00:00:00Z